Literature DB >> 8300593

Cloning and expression of a cDNA for the human prostanoid FP receptor.

M Abramovitz1, Y Boie, T Nguyen, T H Rushmore, M A Bayne, K M Metters, D M Slipetz, R Grygorczyk.   

Abstract

A cDNA clone coding for a functional human prostanoid FP receptor has been isolated from a uterus cDNA library. The human FP receptor consists of 359 amino acid residues with a predicted molecular mass of 40,060, and has the seven putative transmembrane domains characteristic of G-protein-coupled receptors. Challenge of Xenopus oocytes expressing the FP receptor with 10 nM of either prostaglandin (PG) F2 alpha or the selective FP-receptor agonist fluprostenol resulted in an elevation in intracellular Ca2+. Radioreceptor binding studies using membranes prepared from mammalian COS cells transfected with the FP receptor cDNA showed that the rank order of potency for prostaglandins and prostaglandin analogs in competition for [3H]PGF2 alpha specific binding sites was as predicted for the FP receptor, with PGF2 alpha approximately fluprostenol > PGD2 > PGE2 > U46619 > iloprost. In summary, we have cloned the human prostanoid FP receptor which is functionally coupled to the Ca2+ signalling pathway.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8300593

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  PGF(2alpha), a prostanoid released by endothelial cells activated by hypoxia, is a chemoattractant candidate for neutrophil recruitment.

Authors:  T Arnould; R Thibaut-Vercruyssen; N Bouaziz; M Dieu; J Remacle; C Michiels
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Effects of prostaglandin F(2α) on adipocyte biology relevant to graves' orbitopathy.

Authors:  Mohd Shazli Draman; Fiona Grennan-Jones; Lei Zhang; Peter N Taylor; Tommy Kyaw Tun; John McDermott; Paul Moriarty; Daniel Morris; Carol Lane; Seamus Sreenan; Colin Dayan; Marian Ludgate
Journal:  Thyroid       Date:  2013-11-04       Impact factor: 6.568

3.  Neuroprotective effect of latanoprost on rat retinal ganglion cells.

Authors:  Hideyo Kudo; Toru Nakazawa; Masahiko Shimura; Hidetoshi Takahashi; Nobuo Fuse; Kenji Kashiwagi; Makoto Tamai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

Review 4.  Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity.

Authors:  Dejan Milatovic; Thomas J Montine; Michael Aschner
Journal:  Neurotoxicology       Date:  2011-03-03       Impact factor: 4.294

5.  Neuronal cyclooxygenase-2 activity and prostaglandins PGE2, PGD2, and PGF2 alpha exacerbate hypoxic neuronal injury in neuron-enriched primary culture.

Authors:  Wenjin Li; Shasha Wu; Robert W Hickey; Marie E Rose; Jun Chen; Steven H Graham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

6.  Tunicamycin inhibits prostaglandin F2 alpha receptor-mediated phosphoinositide hydrolysis in cultured rat astrocytes.

Authors:  J Kitanaka; T Hamano; M Gotoh; H Hashimoto; A Baba
Journal:  Neurochem Res       Date:  1994-12       Impact factor: 3.996

7.  Prostaglandin and myokine involvement in the cyclooxygenase-inhibiting drug enhancement of skeletal muscle adaptations to resistance exercise in older adults.

Authors:  Todd A Trappe; Robert A Standley; Bozena Jemiolo; Chad C Carroll; Scott W Trappe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-12-05       Impact factor: 3.619

8.  Activation of the human FP prostanoid receptor disrupts mitosis progression and generates aneuploidy and polyploidy.

Authors:  X-B Chen; J W Regan
Journal:  Cell Mol Life Sci       Date:  2006-01       Impact factor: 9.261

9.  EP1- and FP-mediated cross-desensitization of the alpha (alpha) and beta (beta) isoforms of the human thromboxane A2 receptor.

Authors:  Leanne P Kelley-Hickie; B Therese Kinsella
Journal:  Br J Pharmacol       Date:  2004-04-20       Impact factor: 8.739

Review 10.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.